menu
    • menu
    [{"orgOrder":0,"company":"Ziauddin University","sponsor":"Hilton Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"PAKISTAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Saccharomyces Cerevisiae","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Ziauddin University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ziauddin University \/ Hilton Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Ziauddin University \/ Hilton Pharma"},{"orgOrder":0,"company":"Cargill","sponsor":"Natural Immune Systems Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Saccharomyces Cerevisiae","moa":"Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Cargill","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cargill \/ Natural Immune Systems Inc","highestDevelopmentStatusID":"1","companyTruncated":"Cargill \/ Natural Immune Systems Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Saccharomyces Cerevisiae

    Menu

    Saccharomyces Cerevisiae

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cargill

                            Country arrow
                            PREP
                            Not Confirmed

                            Cargill

                            Country arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Natural Immune Systems Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EpiCor Clinical Study on Rapid Immune Modulating Effects

                            Details : Saccharomyces Cerevisiae is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 19, 2023

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Natural Immune Systems Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ziauddin University

                            Country arrow
                            PREP
                            Not Confirmed

                            Ziauddin University

                            Country arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hilton Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Saccharomyces Cerevisiae for Irritable Bowel Syndrome

                            Details : Saccharomyces Cerevisiae is a Probiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            December 08, 2021

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hilton Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lesaffre International

                            Country arrow
                            PREP
                            Not Confirmed

                            Lesaffre International

                            Country arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Biofortis Mérieux Nutriscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Oral Probiotic Yeast on the Composition of the Vaginal Microbiota in Healthy Women

                            Details : Saccharomyces Cerevisiae is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            July 02, 2018

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Biofortis Mérieux Nutriscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lesaffre International

                            Country arrow
                            PREP
                            Not Confirmed

                            Lesaffre International

                            Country arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Saccharomyces Cerevisiae in LDL Cholesterol

                            Details : Saccharomyces Cerevisiae is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Dyslipidemias.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            December 13, 2016

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lesaffre International

                            Country arrow
                            PREP
                            Not Confirmed

                            Lesaffre International

                            Country arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Eurofins CDMO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal C...

                            Details : Saccharomyces Cerevisiae is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Candidiasis, Vulvovaginal.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            January 26, 2015

                            Lead Product(s) : Saccharomyces Cerevisiae

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Eurofins CDMO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth